Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to …
Full PLSE analysis →
Competitive advantage assessment
Key strengths
Conservative LeverageLeverage position is conservative vs peers (score 0.67). Balance sheet flexibility is a strategic asset for serial acquirers.
Key risks
Below-Peer Gross MarginsGross margin quality lags peers (score 0.09). May indicate commodity-like product mix or distributor margin drag.
Weak FCF GenerationFCF margin quality lags peers (score 0.03). Below-peer FCF conversion is a MedTech quality warning.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Where PLSE ranks in Medical Instruments & Supplies
Pulse Biosciences, Inc ranks #58 of 62
scored companies in Medical Instruments & Supplies by moat score — the top 94%.
The widest moat in the group is Intuitive Surgical, Inc. (ISRG)
at 86/100.
Moat scores for companies ranked near PLSE in Medical Instruments & Supplies
How PLSE scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 7
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 18
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 3
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 5
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 42
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 11
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Pulse Biosciences, Inc (PLSE) scores 12 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #58 of 62 scored companies in Medical Instruments & Supplies, the top 94%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Medical Instruments & Supplies. Its strongest defense is Capital Structure & Resilience (42/100) and its weakest is FCF Quality & Cash Conversion (3/100).
How does Pulse Biosciences, Inc compare with other Medical Instruments & Supplies companies?
Pulse Biosciences, Inc ranks #58 of 62 scored companies in Medical Instruments & Supplies by moat score. The widest moat in Medical Instruments & Supplies is Intuitive Surgical, Inc. (ISRG) at 86/100. The companies ranked closest are Sharps Technology Inc. Warrant (STSSW) at 21 just above it and GlucoTrack, Inc. (GCTK) at 9 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Medical Instruments & Supplies. The defenses are then weighted to produce the overall score out of 100.
Why is Pulse Biosciences, Inc scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Pulse Biosciences, Inc?
The Medical Devices & Diagnostics template measures 6 defenses, and PLSE scores: Pricing Power & Consumable Moat (7), R&D Pipeline & Capital Returns (18), FCF Quality & Cash Conversion (3), Commercial Execution (5), Capital Structure & Resilience (42), Growth Durability (11). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.